These results indicate that adding a DNMT1 inhibitor to an ALK inhibitor may achieve deeper blockade of NPM/ALK-driven oncogenic signaling and enhance cell death in ALK+ ALCL cells. The gene discussed is DNMT1; the disease is anaplastic large cell lymphoma.